Timothy Gershon, MD, PhD

Dr. Timothy Gershon is a renowned pediatric neuro-oncologist and leading researcher whose work bridges the gap between developmental neurobiology and pediatric brain tumor therapeutics. Currently serving as a Professor in the Department of Pediatrics at the Emory University School of Medicine and the Director of the Children’s Center for Neurosciences Research, Dr. Gershon has dedicated his career to improving the prognosis for children with malignant brain tumors, particularly medulloblastoma. Furthermore, he is an integral member of the Cell and Molecular Biology Research Program at the Winship Cancer Institute. His laboratory investigates the fundamental mechanisms of brain development to understand how developmental processes are hijacked during oncogenesis. By defining the cellular origins of brain tumors and the metabolic pathways that drive their aggressive growth, Dr. Gershon has been instrumental in identifying novel therapeutic targets that exploit the unique vulnerabilities of tumor cells without harming the developing brain. Clinically, Dr. Gershon translates these bench discoveries into the clinical setting, providing comprehensive care to pediatric patients with complex neurological malignancies. He received his MD and PhD from Columbia University and completed his pediatric and neurology residencies at New York Presbyterian Hospital, followed by a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center, equipping him with a deep understanding of both the clinical challenges and the molecular intricacies of neuro-oncology. As a Scientific Advisor for Curtana Pharmaceuticals, Dr. Gershon’s extensive expertise in developmental neurobiology, tumor metabolism, and pediatric clinical trial design provides invaluable guidance. His insights ensure that Curtana’s targeted therapies are rigorously evaluated and optimized to safely and effectively address the profound unmet medical needs in pediatric neuro-oncology, ultimately striving to deliver life-saving treatments to vulnerable patient populations.